Breast Cancer Deadline 2020 Update

Breast Cancer Deadline 2020 Update

Breast Cancer Awareness Month has come and gone, and with it came a change in the conversation. While the press coverage this year included articles about local runs and survivor stories and reminders to get mammograms, there was a noticeable focus on research to prevent breast cancer. The shift in conversation was not confined to the media. In the public policy realm, Congresswoman Shelley Capito delivered a speech from the floor of the House of Representatives imploring her colleagues to support the Accelerating the End of Breast Cancer Act.

On the radio waves during October, Beyond Pink TEAM advocates Lori Seawel and Christine Carpenter talked about Breast Cancer Deadline 2020® on KXEL 1540 and on KBBG 88.1 FM, respectively. In social media, Breast Cancer Deadline 2020® advocates were encouraged to make #BCD2020 a trending topic on Twitter.

And the conversation among the scientists is shifting as well. At a recent event of the medical faculty and staff at a major medical institution, National Breast Cancer Coalition, NBCC, president Fran Visco asked why she—a patient advocate—was invited to speak about NBCC and its work, when the usual choice would be to invite a doctor or a researcher. Visco was told the medical community is well aware of Breast Cancer Deadline 2020® and not only do they talk about it, the deadline informs their work and they wanted to hear from NBCC what advocates want from the research community.


Through the generous support of the National Philanthropic Trust, NBCC also awarded a grant to Dr. Gregory Hannon, Professor and HHMI Investigator at Cold Spring Harbor Laboratory and Dr. H. Kim Lyerly, George Barth Gellar Professor of Cancer Research, Duke University School of Medicine. Drs. Hannon and Lyerly will collaborate on efforts to evaluate the biology of human ductal carcimona in situ (DCIS) through sequencing (RNAseq). DCIS is not cancer, yet it is treated as such. Many women with DCIS receive toxic therapy that will not help them, but will cause harm. Addressing the issue of DCIS is part of NBCC’s Artemis Project®. Investigators will use next-generation sequencing to generate profiles from single (DCIS) lesions and will carry out laboratory tests to evaluate signaling and immune responses. Further, the investigators plan to determine whether differences among DCIS lesions relate to different subtypes of invasive breast cancer. Another goal of the research is to analyze the healthy tissue surrounding DCIS lesions, to gain a better understanding of how disease progresses from DCIS to invasive cancer.

To learn more about the Breast Cancer Deadline 2020, the Artemis Project, or the National Breast Cancer Coalition check out


Posted in Advocacy, From the Team